Acesso livre
Acesso livre

Saúde Pública/Medicina Humanitária

Vacina da Moderna pode ser superior à vacina da Pfizer contra a variante Delta.

12 Ago, 2021 | 12:25h

Moderna may be superior to Pfizer against delta variant — breakthrough odds rise with time – CNBC

Estudo original 1 (preprint): Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence – medRxiv

Estudo original 2 (preprint): Neutralizing antibody responses to SARS-CoV-2 variants in vaccinated Ontario long-term care home residents and workers – medRxiv

Conteúdo relacionado: Study shows AstraZeneca and Pfizer vaccines are effective against Delta variant, but both doses are needed.

[Preprint] Efetividade das vacinas da Pfizer vs. Moderna contra a variante Delta da COVID-19 no Catar – A efetividade contra doença sintomática causada pela variante Delta foi de 53,5% para a vacina da Pfizer e de 84,8% para a da Moderna; a efetividade contra doença grave pela mesma variante foi de 89,7% para Pfizer e de 100% para a Moderna.

12 Ago, 2021 | 12:23h

BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the Delta (B.1.617.2) variant in Qatar – medRxiv

Conteúdo relacionado: Study shows AstraZeneca and Pfizer vaccines are effective against Delta variant, but both doses are needed.

 

Comentário no Twitter

 

Estudo clínico Solidarity da OMS entra em uma nova fase com 3 novas drogas candidatas.

12 Ago, 2021 | 12:18h

WHO’s Solidarity clinical trial enters a new phase with three new candidate drugs – World Health Organization

Comentário: WHO-led Trial Will Test Malaria and Cancer Medicines Against COVID-19 – Health Policy Watch

Conteúdos relacionados:

A giant trial of COVID-19 treatments organized by the WHO is restarting. Here are the drugs it’s betting on.

WHO Solidarity trial to restart with focus on drugs that act on immune responses caused by Covid-19.

 

Comentário no Twitter (fio – clique para saber mais)

 

Vacinação: Efetividade versus eficácia.

12 Ago, 2021 | 12:17h

Vaccination: Effectiveness versus Efficacy – by Luis Correa, MD

Vídeo | Perguntas frequentes sobre vacinação contra COVID-19 – Atualizações de agosto de 2021.

12 Ago, 2021 | 12:15h

Frequently Asked COVID-19 Vaccine Questions – August 2021 Update – JAMA

Estudo randomizado | Cabotegravir injetável de ação longa para prevenção de infecção por HIV em homens cisgênero e mulheres transgênero.

12 Ago, 2021 | 12:07h

Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women – New England Journal of Medicine

Vacinas aplicadas nos últimos 20 anos podem evitar 50 milhões de mortes em países de baixa e média rendas.

12 Ago, 2021 | 12:00h

Vaccines given in last 20 years could prevent 50 million deaths in LMICs – Imperial College London

Estudo original: Lives saved with vaccination for 10 pathogens across 112 countries in a pre-COVID-19 world – eLife

Diretriz OMS para vigilância das variantes do SARS-CoV-2.

11 Ago, 2021 | 11:00h

Guidance for surveillance of SARS-CoV-2 variants: Interim guidance, 9 August 2021 – World Health Organization

 

Comentário no Twitter (fio – clique para saber mais)

 

M-A | Infecção assintomática por SARS-CoV-2 – “Estima-se que a porcentagem de infecções que não levaram a sintomas clínicos, portanto, de fato assintomáticas, foi em torno de 35,1%.”

11 Ago, 2021 | 10:58h

Asymptomatic SARS-CoV-2 infection: A systematic review and meta-analysis – Proceedings of the National Academy of Sciences

 

Comentário no Twitter

 

M-A | Mais de 50 efeitos de longo prazo da COVID-19.

11 Ago, 2021 | 10:57h

More than 50 long-term effects of COVID-19: a systematic review and meta-analysis – Scientific Reports

Conteúdos relacionados:

Illness duration and symptom profile in symptomatic school-aged children tested for SARS-CoV-2 – “Only 25 (1.8%) of 1379 children experienced symptoms for at least 56 days.”

Cohort study: Risk factors for long covid in previously hospitalized children.

Viewpoint: The road to addressing Long Covid.

Review: Long covid—mechanisms, risk factors, and management.

Review: Symptoms, complications and management of long COVID.

Long Covid: fatigue, post-exertional malaise, and cognitive dysfunction are the most common symptoms, according to an international survey.

Studies elucidate poorly understood long COVID.

Long-term Symptoms After SARS-CoV-2 Infection in Children and Adolescents – “This study found a low prevalence of symptoms compatible with long COVID in a randomly selected cohort of children assessed 6 months after serologic testing”.

Long Covid: 39% of patients report persistent symptoms more than seven months after diagnosis of COVID-19 in an outpatient setting.

[Preprint] Long Covid: Persistent symptoms following SARS-CoV-2 infection in a random community sample of 508,707 people.

Long COVID or post-acute sequelae of COVID-19 (PASC): An overview of biological factors that may contribute to persistent symptoms.

Long Covid: Half of young adults with COVID-19 have persistent symptoms 6 months after, study finds.

[Preprint] Long Covid: Third of people infected have long term symptoms.

Opinion | Causation or confounding: why controls are critical for characterizing long COVID – “Many of the self-reported symptoms, such as intermittent headaches or tiredness, are nonspecific and prevalent in the general population”.

Almost 25% of COVID-19 patients develop long-lasting symptoms, according to a new report.

Perspective | The four most urgent questions about long COVID.

Systematic review: Frequency, signs and symptoms, and criteria adopted for long COVID-19.

Report: 376,000 people in UK have had long Covid symptoms for at least a year.

Systematic review of 45 studies including 9751 participants, most of which were hospitalized, found 73% had at least 1 persistent symptom for weeks after Covid-19.

COVID Morbidity – The emerging burden of long COVID is significant, and needs to be considered when evaluating the risk vs. benefit of pandemic measures.

One year after hospital discharge due to SARS-CoV-2 Infection, the prevalence of long-term cough, chest pain, dyspnea, and fatigue was 2.5%, 6.5%, 23.3%, and 61.2%, respectively

Population-based cohort study: Non-hospitalized COVID-19 patients have low-risk of serious long-term effects, but visits to general practitioners and outpatient hospital visits are increased.

One third of patients hospitalized with COVID-19 have lung changes after a year

Long Covid: Largest post-acute COVID-19 study to date examined the health outcomes in more than 73,000 people who’d had COVID-19 and were not hospitalized

Study shows low incidence of post-acute COVID-19 symptoms (“Long Covid”) in children after mild disease

Perspective | They Tested Negative for Covid. Still, They Have Long Covid Symptoms.

Large study finds 1 in 3 Covid-19 survivors have subsequent mental health and neurological conditions

Cohort study: One in ten have long-term effects 8 months following mild COVID-19

Long Covid Implications for the workplace

Long Covid in the UK – More than a million affected in February, survey suggests

Covid-19: Middle aged women face greater risk of debilitating long term symptoms

Persistent neurologic symptoms and cognitive dysfunction in non‐hospitalized Covid‐19 “long haulers”

Opinion | We need to start thinking more critically — and speaking more cautiously — about long Covid

Review | Post-acute COVID-19 syndrome

Long Covid | Four-month clinical status of a cohort of patients after hospitalization for COVID-19

Perspective | Long Covid isn’t as unique as we thought

Attributes and predictors of long COVID

WHO Report: Preparing for Long COVID 2021

Long Covid: Sequelae in adults at 6 Months after COVID-19 infection

How many people get ‘long COVID’ – and who is most at risk?

Long Covid: Respiratory and psychophysical sequelae among patients with COVID-19 four months after hospital discharge

Managing the long term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guideline

Patients, clinicians seek answers to the mystery of ‘Long COVID’

Long Covid: 6-month consequences of COVID-19 in patients discharged from hospital

[Preprint] Characterizing Long COVID in an International Cohort: 7 Months of Symptoms and Their Impact

NICE Guideline: Managing the long-term effects of COVID-19

 

Comentário no Twitter

 

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.